Expression of polysialic acid in primary laryngeal squamous cell carcinoma

Klobučar, Marko; Visentin, Sarah; Jakovčević, Antonija; Bilić, Mario; Bilić, Lana Kovač; Đanić, Davorin; Pavelić, Krešimir; Pavelić, Sandra Kraljević

doi:10.1016/j.lfs.2017.02.002

Cited by 5 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, we showed that the expression of polySia was detected in laryngeal squamous cell carcinoma biopsies specimens with generally stronger immunoreactivity in nonmetastatic tumor laryngeal squamous cell carcinoma sections and in histologically undifferentiated tumors. In addition, we provided evidence of an increased polysialyltransferase IV (ST8SiaIV) expression involved in polySia synthesis in both metastatic and nonmetastatic primary tumors, which is accompanied by decreased levels of FGFR1, Erk 1/2, and c‐Raf .…”

Section: Sialylation and Metastasesmentioning

confidence: 94%

Glycosylation and metastases

2018

View full text Add to dashboard Cite

The change of cellular glycosylation is one of the key events in malignant transformation and neoplastic progression, and tumor‐related glycosylation alterations are promising targets in both tumor diagnosis and therapy. Both malignant transformation and neoplastic progression are the consequence of gene expression alterations and alterations in protein expression. Micro environmental factors such as extracellular matrix (ECM) also play an important role in their growth and metastasis. Tumor‐associated glycans are important biomarker candidates for cancer diagnosis and prognosis, and analytical methods for their detection were developed recently. Glycoproteomics that use mass spectrometry for identification of cancer antigens and structural analysis of glycans play a key role in the investigation of changes of glycosylation during malignant transformation and tumor development and metastasis. Deep understanding of glycan remodeling in cancer and the role of glycosyltransferases that are involved in this process will require a detailed profiling of glycosylation patterns of tumor cells, and corresponding analytical methods for their detection were developed.

show abstract

Section: Sialylation and Metastasesmentioning

confidence: 94%

Glycosylation and metastases

2018

View full text Add to dashboard Cite

show abstract

“…It was demonstrated that the autopolysialylation of ST8SiaII/ST8SiaIV was required for recognition and subsequent polysialylation of substrates such as neuropilin-2 (NRP-2), SynCAM 1, and NCAM [290]. Although PSA is virtually absent in most adult tissues, it is re-expressed during the progression of some malignant tumors, such as neuroblastoma [291], breast cancer [292], laryngeal squamous cell carcinoma [293], pancreatic cancer [294], non-small cell lung cancer [295], and small cell lung cancer [296]. The most important physical feature of PSA is its anti-adhesive effect, favoring invasion and metastasis, but PSA chains also allow for the regulation of signal transduction via influencing the access of ligands to their receptors.…”

Section: Polysialic Acidmentioning

confidence: 99%

Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives

Berois

Pittini

Osinaga

2022

Cancers

View full text Add to dashboard Cite

Aberrant glycosylation is a hallmark of cancer and can lead to changes that influence tumor behavior. Glycans can serve as a source of novel clinical biomarker developments, providing a set of specific targets for therapeutic intervention. Different mechanisms of aberrant glycosylation lead to the formation of tumor-associated carbohydrate antigens (TACAs) suitable for selective cancer-targeting therapy. The best characterized TACAs are truncated O-glycans (Tn, TF, and sialyl-Tn antigens), gangliosides (GD2, GD3, GM2, GM3, fucosyl-GM1), globo-serie glycans (Globo-H, SSEA-3, SSEA-4), Lewis antigens, and polysialic acid. In this review, we analyze strategies for cancer immunotherapy targeting TACAs, including different antibody developments, the production of vaccines, and the generation of CAR-T cells. Some approaches have been approved for clinical use, such as anti-GD2 antibodies. Moreover, in terms of the antitumor mechanisms against different TACAs, we show results of selected clinical trials, considering the horizons that have opened up as a result of recent developments in technologies used for cancer control.

show abstract

“…Western blotting is a widely-used technique for evaluating relative expression levels of polysialylated-proteins in biological samples (von Der Ohe et al, 2002;Korja et al, 2009;Valentiner, Muhlenhoff, Lehmann, Hildebrandt, & Schumacher, 2011;Nishimura et al, 2014;Westphal, Kleene, Lutz, Theis, & Schachner, 2016;Abe et al, 2017;Chen, Ren, Zhang, Troy, & Wang, 2017;Klobucar et al, 2017). Similarly to ELISA, Western blotting also recognises polySia proteins via immunodetection.…”

Section: Western Blotting (Semi-quantitative)mentioning

confidence: 99%